Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO RoBOT: Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma
NCT07516366Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2027
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in clear cell renal cell carcinoma (ccRCC), sponsored by National Cancer Institute. Planned start May 2027; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07516366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516366.